

PRIVATE OFFERING MEMORANDUM

PROSPECTUS 2026

A strategic acquisition opportunity in a coined, category-flexible .com brand built at the intersection of genome intelligence and nominal value.

INDICATIVE VALUATION

$499,000

Subject to definitive agreement, diligence, transfer and escrow terms.

INVESTMENT THESIS

Genominal is a compact, memorable tradeword with immediate semantic tension: genome supplies scientific authority; nominal supplies commercial, financial and pricing relevance. The combined term is neither a descriptive commodity nor an arbitrary string. It is an ownable verbal asset capable of supporting biotechnology, genomic analytics, AI-enabled diagnostics, pricing infrastructure, insurance, research tooling or a future category not yet named.

CONTACT +1 FIRZTLY 411 FIRZTLYCEO@GMAIL.COM

THE INDUSTRY

MARKET STRUCTURE

Scarcity with operating utility

Premium domains are scarce digital infrastructure. A strong name compresses explanation, lowers recall friction, supports trust and remains portable across product cycles. Unlike a media campaign, a domain is not consumed when the quarter ends; it can remain on the balance sheet, in brand architecture and in customer memory for years.

CAPITAL LOGIC

Expense versus enduring asset

Advertising commonly produces a current-period expense and must be purchased again to sustain reach. An acquired domain may qualify as an intangible asset under the purchaser's accounting framework, with capitalization, impairment and amortization treatment determined by applicable standards, useful-life assumptions and professional advice.

DEMAND DRIVERS

Convergence creates naming pressure

AI, precision medicine, genomics, diagnostics and data infrastructure are converging. Names that credibly span scientific and commercial vocabularies are unusually useful because they reduce future renaming risk. Genominal is broad enough for platform expansion yet specific enough to imply a coherent genome-to-value proposition.

NOMINAL PRICING ASSOCIATION

A financially literate second meaning

"Nominal" carries multiple executive-grade associations: stated value, face value, modest pricing, benchmark pricing and controlled variance. In a commercial context, that subliminal framing can support themes of precision, transparency and disciplined economics. Coupled with "genome," the name suggests the ability to convert complex biological information into a clear, actionable value.

WHY THE CATEGORY MATTERS

Category creation optionality

The strongest digital assets do not merely describe an existing market. They permit the buyer to define one. "Genominal" can function as a company name, platform name, methodology, index, data standard or product family. That optionality matters because the acquisition cost is paid once, while strategic applications can compound across years, jurisdictions and product lines.

2

THE PURCHASER

PRIMARY BUYER

Strategic enterprise acquirer

A scaled biotechnology, diagnostic, pharmaceutical, insurer, healthcare-data or AI company seeking a global brand with scientific credibility and financial fluency. The ideal acquirer understands that naming is not cosmetic; it is a strategic interface between product, capital, customer trust and market position.

CORPORATE TRIGGER

When the asset becomes urgent

Likely triggers include a new platform launch, genomic-data initiative, precision-pricing engine, portfolio consolidation, post-merger rebrand or expansion from a narrow product into a broader operating system. The name is particularly useful when management wants one umbrella that can hold multiple products, markets and future acquisitions.

ECONOMIC BUYER

Balance-sheet decision maker

The decision is most naturally sponsored by a CEO, CFO, chief strategy officer or business-unit president. These buyers can compare the acquisition against recurring media spend, rebranding risk, customer-acquisition friction and the cost of surrendering the name to a competitor.

BOARD-LEVEL RATIONALE

Control, not decoration

A board can evaluate Genominal as a finite strategic asset: one purchase price, global usability, low carrying cost and potential exclusion value. The relevant question is not whether a domain "costs" $499,000. It is whether controlling the category-defining word reduces future brand spend, protects enterprise value and increases strategic freedom by more than that amount.

INTEGRATION THESIS

Acquire once; deploy in phases

The name can be activated gradually. A purchaser may initially use it for a flagship product, research initiative or innovation lab, then elevate it to master brand status once market evidence accumulates. This staged deployment preserves optionality while immediately preventing competitive acquisition.

3

THE COMPETITION

COMPETITIVE SET

Who else may want it

The relevant competitors are not limited to other domain investors. They include healthcare platforms, genomic-data companies, diagnostics firms, AI laboratories, insurers and pharmaceutical companies competing for credible language at the intersection of biology, data and value.

SUBSTITUTION RISK

What substitutes sacrifice

Alternatives are typically longer, more literal or more restrictive: two-word compounds, hyphenated constructions, non-.com extensions or names tied to a single product. These substitutes may function operationally, but they rarely deliver the same compression, memorability, authority or category range.

EXCLUSION VALUE

The value of keeping it away

Ownership prevents a competitor from using the term as a platform, benchmark or strategic narrative. For a well-capitalized buyer, the defensive value may be material even before active deployment. A name can influence market framing simply by being unavailable to others.

MEMORABILITY AND SIMPLICITY

Easy to learn; difficult to replace

Genominal is four syllables, phonetic, visually balanced and built from two familiar roots. It can be spoken in a boardroom, remembered after one exposure and typed without instruction. The word feels invented but immediately interpretable - a rare combination that supports both trademark distinctiveness and market comprehension.

EXCEPTIONAL TRADEWORD

One word, several strategic readings

Its exceptional quality lies in semantic multiplication. The word can mean genome made nominal, genome-to-value, biological benchmarking, genomic commerce or the named standard for a new market. The buyer is not purchasing a single slogan. It is acquiring a compact language system that can hold strategy, products and valuation logic at once.

4

COMPS FROM 2026 TOP 10 DOMAIN SALES

2026 SALE
AI.com
$70.0M

2026 SALE
Club.com
$10.0M

2026 SALE
Green.com
$7.5M

2026 SALE
NAS.com
$1.25M

2026 SALE
Bot.ai
$1.20M

2026 SALE
Midnight.com
$1.15M

2026 SALE
HighLevel.com
$1.00M

2026 SALE
Derm.com
$825K

2026 SALE
Wisdom.ai
$750K

2026 SALE
Defining.com
$500K

COMPARABLE LOGIC

Positioning the valuation

The proposed $499,000 valuation sits below the publicly reported 2026 transactions shown above and near the lower boundary of the year's headline tier. Genominal is not a one-word dictionary .com, so direct equivalence would be inappropriate. Its case instead rests on coined-brand economics: semantic relevance, corporate usability, scarcity, memorability and the possibility that one strategic buyer can extract value far beyond resale comparables.

INVESTMENT CONCLUSION

A finite asset with compounding use

At $499,000, the purchaser acquires a globally usable .com, an immediately intelligible tradeword, a defensible category narrative and permanent exclusion of competitors. The price should be evaluated against the lifetime cost of naming, customer education, repeated advertising and future rebranding - not against annual registration fees. For the right enterprise, Genominal is less a marketing line item than a long-duration strategic asset.

5

Market data: DNJournal 2026 YTD charts; NameBio 2026 Top 100; reported transactions current as of July 16, 2026. Public domain sales represent only disclosed transactions and may not reflect total market activity.

This prospectus is marketing material, not an independent appraisal, securities offering, tax opinion or accounting advice. Purchasers should conduct legal, trademark, technical, financial and tax diligence.